Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCAMARGO, Carlos Henrique-
dc.contributor.authorYAMADA, Amanda Yaeko-
dc.contributor.authorSOUZA, Andreia Rodrigues de-
dc.contributor.authorCUNHA, Marcos Paulo Vieira-
dc.contributor.authorFERRARO, Pedro Smith Pereira-
dc.contributor.authorSACCHI, Claudio Tavares-
dc.contributor.authorSANTOS, Marlon Benedito dos-
dc.contributor.authorCAMPOS, Karoline Rodrigues-
dc.contributor.authorTIBA-CASAS, Monique Ribeiro-
dc.contributor.authorFREIRE, Maristela Pinheiro-
dc.contributor.authorBARRETTI, Pasqual-
dc.identifier.citationSCIENTIFIC REPORTS, v.13, n.1, article ID 14603, 9p, 2023-
dc.description.abstractCarbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy. Therefore, evaluation of novel antimicrobial drugs is needed to identify potential treatments with better outcomes. We evaluated the in vitro activity of novel antimicrobial drugs/combinations against 97 KPC-producing Klebsiella pneumoniae isolates recovered from different hospitals in Brazil during 2021-2022. Clonality, resistance and virulence genes were detected by whole-genome sequencing. The majority of the isolates (54.6%) were classified as extensively drug resistant or multidrug resistant (44.3%); one isolate showed a pandrug resistance phenotype. The most active antimicrobial agents were meropenem-vaborbactam, cefiderocol, and ceftazidime-avibactam, with sensitivities higher than 90%; resistance to ceftazidime-avibactam was associated with KPC-33 or KPC-44 variants. Colistin and polymyxin B were active against 58.6% of the isolates. The 97 isolates were distributed into 17 different sequence types, with a predominance of ST11 (37.4%). Although high in vitro susceptibility rates were detected for meropenem-vaborbactam and cefiderocol, only ceftazidime-avibactam is currently available in Brazil. Our findings showed limited susceptibility to antimicrobial drugs employed for infection treatment of carbapenem-resistant K. pneumoniae, underscoring the urgent need for stringent policies for antimicrobial stewardship to preserve the activity of such drugs.eng
dc.description.sponsorshipInvestigator Sponsored Research-
dc.description.sponsorshipSao Paulo Research Foundation FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [2020/06157-2, 2017/50333-7, 2018/21192-9]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [402158/2021-0]-
dc.description.sponsorshipFESIMA (Fundo Especial de Saude para Imunizacao em Massa e Controle de Doencas)-
dc.publisherNATURE PORTFOLIOeng
dc.relation.ispartofScientific Reports-
dc.titleGenomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates from Brazilian hospitalseng
dc.rights.holderCopyright NATURE PORTFOLIOeng
dc.subject.wosMultidisciplinary Scienceseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Andreia Rodrigues de:Adolfo Lutz Inst, Ctr Bacteriol, Ave Dr Arnaldo 351,9 Andar, BR-01246902 Sao Paulo, SP, Brazil-, Marcos Paulo Vieira:Adolfo Lutz Inst, Ctr Bacteriol, Ave Dr Arnaldo 351,9 Andar, BR-01246902 Sao Paulo, SP, Brazil-, Pedro Smith Pereira:Adolfo Lutz Inst, Ctr Bacteriol, Ave Dr Arnaldo 351,9 Andar, BR-01246902 Sao Paulo, SP, Brazil-, Claudio Tavares:Adolfo Lutz Inst, Lab Estrateg, Ave Dr Arnaldo 351,10 Andar, BR-01246902 Sao Paulo, Brazil-, Marlon Benedito dos:Adolfo Lutz Inst, Lab Estrateg, Ave Dr Arnaldo 351,10 Andar, BR-01246902 Sao Paulo, Brazil-, Karoline Rodrigues:Adolfo Lutz Inst, Lab Estrateg, Ave Dr Arnaldo 351,10 Andar, BR-01246902 Sao Paulo, Brazil-, Monique Ribeiro:Adolfo Lutz Inst, Ctr Bacteriol, Ave Dr Arnaldo 351,9 Andar, BR-01246902 Sao Paulo, SP, Brazil-, Pasqual:Univ Estadual Paulista, Fac Med Botucatu, Ave Prof Montenegro,S-N, BR-18618687 Botucatu, Brazil-
hcfmusp.relation.referenceAndrade LN, 2011, ANTIMICROB AGENTS CH, V55, P3579, DOI 10.1128/AAC.01783-10eng
hcfmusp.relation.referenceBartolleti F, 2016, EMERG INFECT DIS, V22, P1849, DOI 10.3201/eid2210.160695eng
hcfmusp.relation.referenceBonnin RA, 2020, EMERG INFECT DIS, V26, P1212, DOI 10.3201/eid2606.191517eng
hcfmusp.relation.referenceBush K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00047-19eng
hcfmusp.relation.referenceCarattoli A, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00574-21eng
hcfmusp.relation.referenceCenters for Disease Control and Prevention Prevention U. S. C. for D. C. and & (CDC) C. for D. C. and P., 2013, US DEP HEAL HUM SERV, P1, DOI [DOI 10.15620/CDC:82532, 10.15620/CDC:82532]eng
hcfmusp.relation.referenceChen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008eng
hcfmusp.relation.referenceCommunity G., 2022, NUCLEIC ACIDS RES, DOI 10.1093/nar/gkac247eng
hcfmusp.relation.referenceConceiçao-Neto OC, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.898125eng
hcfmusp.relation.referenceCuzon G, 2010, EMERG INFECT DIS, V16, P1349, DOI 10.3201/eid1609.091389eng
hcfmusp.relation.referenceDi Bella S, 2021, J GLOB ANTIMICROB RE, V25, P268, DOI 10.1016/j.jgar.2021.04.001eng
hcfmusp.relation.referenceGalani I, 2021, EUR J CLIN MICROBIOL, V40, P219, DOI 10.1007/s10096-020-04000-9eng
hcfmusp.relation.referenceHansen GT, 2021, INFECT DIS THER, V10, P75, DOI 10.1007/s40121-020-00395-2eng
hcfmusp.relation.referenceIskandar K, 2021, ANTIMICROB RESIST IN, V10, DOI 10.1186/s13756-021-00931-weng
hcfmusp.relation.referenceJiang M, 2022, INFECT DRUG RESIST, V15, P4627, DOI 10.2147/IDR.S371285eng
hcfmusp.relation.referenceKarakonstantis S, 2022, ANTIBIOTICS-BASEL, V11, DOI 10.3390/antibiotics11060723eng
hcfmusp.relation.referenceKatoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010eng
hcfmusp.relation.referenceKuo SC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105883eng
hcfmusp.relation.referenceMagiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.xeng
hcfmusp.relation.referenceFortaleza CMCB, 2017, J HOSP INFECT, V96, P139, DOI 10.1016/j.jhin.2017.03.024eng
hcfmusp.relation.referenceSampaio JLM, 2016, BRAZ J MICROBIOL, V47, P31, DOI 10.1016/j.bjm.2016.10.002eng
hcfmusp.relation.referenceMigliorini LB, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10030332eng
hcfmusp.relation.referenceMinh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015eng
hcfmusp.relation.referencePage AJ, 2015, BIOINFORMATICS, V31, P3691, DOI 10.1093/bioinformatics/btv421eng
hcfmusp.relation.referencePaul M, 2022, CLIN MICROBIOL INFEC, V28, P521, DOI 10.1016/j.cmi.2021.11.025eng
hcfmusp.relation.referencePereira LB, 2021, REV SOC BRAS MED TRO, V54, DOI 10.1590/0037-8682-0861-2020eng
hcfmusp.relation.referencePoirel L, 2017, CLIN MICROBIOL REV, V30, P557, DOI 10.1128/CMR.00064-16eng
hcfmusp.relation.referencePoirel L, 2011, DIAGN MICR INFEC DIS, V70, P119, DOI 10.1016/j.diagmicrobio.2010.12.002eng
hcfmusp.relation.referencePorto APM, 2020, J HOSP INFECT, V104, P165, DOI 10.1016/j.jhin.2019.10.016eng
hcfmusp.relation.referenceRibot EM, 2006, FOODBORNE PATHOG DIS, V3, P59, DOI 10.1089/fpd.2006.3.59eng
hcfmusp.relation.referenceRossi F, 2017, BRAZ J INFECT DIS, V21, P98, DOI 10.1016/j.bjid.2016.09.011eng
hcfmusp.relation.referenceRossi F, 2011, CLIN INFECT DIS, V52, P1138, DOI 10.1093/cid/cir120eng
hcfmusp.relation.referenceSpadar A, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-17996-1eng
hcfmusp.relation.referenceSun DX, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.01694-17, 10.1128/AAC.01694-17]eng
hcfmusp.relation.referenceTacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/s1473-3099(17)30753-3, 10.1016/S1473-3099(17)30753-3]eng
hcfmusp.relation.referenceWang YH, 2020, J GLOB ANTIMICROB RE, V22, P18, DOI 10.1016/j.jgar.2019.12.009eng
hcfmusp.relation.referenceWHO, 2017, GLOBAL PRIORITY LISTeng
hcfmusp.relation.referenceWick RR, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005595eng
hcfmusp.relation.referenceWyres KL, 2020, NAT REV MICROBIOL, V18, P344, DOI 10.1038/s41579-019-0315-1eng
hcfmusp.relation.referenceXu CJ, 2022, MICROBIOL SPECTR, DOI 10.1128/spectrum.01390-22eng
hcfmusp.relation.referenceYao JH, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.741940eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/47
LIM/47 - Laboratório de Hepatologia por Vírus

Artigos e Materiais de Revistas Científicas - LIM/49
LIM/49 - Laboratório de Protozoologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_CAMARGO_Genomic_analysis_and_antimicrobial_activity_of_βlactamβlactamase_inhibitors_2023.PDFpublishedVersion (English)2.27 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.